Yoshida S, et al. - Authors gauged if remission can be sustained for rheumatoid arthritis (RA) patients after tapering abatacept (ABT). The mean age of the participants included in the study was 68.7 ± 10.2 years, mean disease duration was 7.7 ± 10.2 years. In order to sustain remission in patients with RA, ABT tapering is a promising short-term strategy and for monitoring disease activity after tapering ABT, ultrasonography is a useful tool. The predictors of an elevated total PD score after tapering ABT therapy were longer disease duration, higher DAS28-CRP at 24 weeks, and higher total PD score at 24 weeks.